Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
The Tavneos story is getting more bizarre by the day: since January 2026 FDA is haggling with Amgen about a withdrawal. The Agency’s reasoning is described in detail in their April 26 statement and mentioned in numerous Pharma newsletters. The key issue is and was the unblinded re-adjudication of the Continue reading The Never-Ending TAVNEOS Story
Today we discuss the group of BAFF/APRIL inhibitors, specifically the three TACI mAb constructs that are currently in development. They were tested in a broad gamut of B-cell indications but failed to show efficacy in many. So far, consistent clinical success has been seen only in IgA nephropathy (IgAN), with Continue reading BAFF / APRIL Inhibitors Homing in on IgAN